0
0.5
1
1.5
2+
Mortality
86%
Improvement
Relative Risk
Symp. case
82%
Symp. case (b)
76%
Tixagevimab/c.. PROVENT Prophylaxis DB RCT
Is prophylaxis with tixagevimab/cilgavimab beneficial for COVID-19?
Double-blind RCT 5,172 patients in multiple countries (Nov 2020 - Mar 2021)
Fewer symptomatic cases with tixagevimab/cilgavimab (p<0.000001)
c19early.org
Levin et al., New England J. Medicine, Apr 2022
Favors tixagevimab/ci..
Favors control